摘要
目的对尿毒症透析患者血清中晚期糖基化终末产物(AGEs)进行测定并对其影响因素进行分析,指导临床治疗。方法20例尿毒症患者,接受血液透析滤过联合高通量透析(HDF+HFHD)组10例,接受常规血液透析(CHD)组10例,用荧光分光光度计法对透析患者血清AGEs水平进行测定(治疗6个月前后以及单次HDF、HFHD、CHD治疗前后),并对影响因素进行分析。结果尿毒症透析患者AGEs水平与年龄、透析时间、有无残余尿量等无显著相关(P>0.05),与透析方式显著相关(P<0.05);单次HDF、HFHD治疗血清AGEs水平较透析前均明显下降(P<0.05),但两组间差异无统计学意义(P>0.05),单次CHD治疗血清AGEs水平差异无统计学意义(P>0.05);HDF+HFHD组、CHD组内6个月治疗后透前AGEs水平差异均无统计学意义(P>0.05),但组间差异有统计学意义,HDF+HFHD组明显低于CHD组(P<0.05)。结论透析方式是影响尿毒症患者血清AGEs水平的主要因素;长期血液透析滤过联合高通量透析对AGEs清除作用明显优于常规血液透析治疗;HDF、HFHD治疗是清除尿毒症患者体内AGEs的一条重要途径。
Objective To investigate the influence of various blood purification methods on the advanced glycation end-products （AGEs） in uremia patients. Methods Twenty uremia patients purified with various blood purifications were divided into two groups as HDF＋ HFHD group and CHD group. The AGEs was measured by immunofluorescence spectrophotometry respectively before treatment,after a blood purification session and six months, and the relative factors were analysed. Results There was a significant difference between AGEs and various blood purification methods. There was no correlation between AGEs and age, duration of dialysis, residual urine and drugs （P 〉 0. 05）. There was a significant difference between the pre-dialysis and post-dialysis values of AGEs in HDF and HFHD,while there was no significant difference in CHD（ P 〉0. 05）. Before and after six month treatment, the levels of AGEs between two groups were no significant difference（ P 〉 0.05）, the levels of AGEs in HDF＋HFHD group were significantly lower than those in CHD group（ P〈0.05）. Conclusion The AGEs levels correlated with various blood purification methods. The AGEs level was lower in the patients with long-term HDF＋ HFHD than with CHD. HDF and HFHD may be important dialysis modalities cleaning AGEs in uremia patients.
出处
《临床荟萃》
CAS
北大核心
2007年第22期1606-1609,共4页
Clinical Focus
关键词
尿毒症
糖基化终产物
高级
血液透析滤过
uremia
glycosylation end-products, advanced
hemodiafiltration
